Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Medicenna Therapeutics Corp. T.MDNA

Alternate Symbol(s):  MDNA

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:MDNA)

Fundamentals Snapshot (TSX:MDNA)

Opinion & Analysis (TSX:MDNA)

No current opinion is available.

Bullboard Posts (TSX:MDNA)

Medicenna (TSX:MDNA) drug stimulates anti-cancer response

https://themarketherald.ca/medicenna-announces-new-clinical-data-showing-dose-dependent-stimulation-of-anti-cancer-immune-cells-with...
carolinegan - May 6, 2022

PR

Good News. Not sure what the market is waiting for ?!
windymayor1 - January 26, 2022

Peer-Reviewed Publication of Preclinical Data on MDNA11

MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to...
Betteryear2 - January 26, 2022

mdna 52 week high very possible, very soon

$mdna 52 week high of $6.82. If it was done once, it can be done again, esp with big catalyst in less than one month!
HarryGluten - November 17, 2021

mdna 55 deal

This would be huge: Resesarch Capital Analyst Uddin believes efforts to secure deal for $MDNA 55 prior to start of Phase 3 clinical...
HarryGluten - November 17, 2021

Research Capital price target of $6.90

$mdna   Canadian biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) has lost a...
HarryGluten - November 17, 2021